TRAX (First Tracks Biotherapeutics) Interest Expense: $ Mil (TTM As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Interest Expense?

First Tracks Biotherapeutics TRAX +11.85% 12 Interest Expense is $ Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. First Tracks Biotherapeutics's interest expense for the six months ended in Dec. 2024 was $ 0.00 Mil. First Tracks Biotherapeutics does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Dec. 2024.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. First Tracks Biotherapeutics's Operating Income for the six months ended in Dec. 2024 was $ -181.10 Mil. First Tracks Biotherapeutics's Interest Expense for the six months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate First Tracks Biotherapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

First Tracks Biotherapeutics  (NAS:TRAX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

First Tracks Biotherapeutics's Interest Expense for the six months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the six months ended in Dec. 2024 was $-181.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was $14.11 Mil.

First Tracks Biotherapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate First Tracks Biotherapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. First Tracks Biotherapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

First Tracks Biotherapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Interest Expense Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Interest Expense
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Interest Expense 0.00 0.00
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $ Mil mean?
First Tracks Biotherapeutics (TRAX) has a Interest Expense of $ Mil as of Dec. 2024. Interest Expense is the amount a company pays on its long-term debt. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Interest Expense too high?
First Tracks Biotherapeutics' current Interest Expense is $ Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Interest Expense compare to ALT and RGNX?
First Tracks Biotherapeutics' Interest Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Interest Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Interest Expense of $ Mil. The current Interest Expense is $ Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Interest Expense is $ Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price